文献速递消化道肿瘤放疗放疗物理与技术

椎体与脾脏照射与接受立体定向体部放疗的局限性胰腺癌患者淋巴细胞减少相关

Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy.
PubMed 文献 · Radiat Oncol · 2021-12-24

本研究纳入132例接受立体定向体部放疗的临界可切除或局部晚期胰腺癌患者,回顾性勾画T11-L3椎体与脾脏并分析剂量学与淋巴细胞减少的关系。椎体V15、V2.5及脾脏V10与≥2级淋巴细胞减少发生相关,椎体V15≥5.84%、V2.5≥48.36%、脾脏V10≥4.17%者发生率更高。作者认为优化椎体与脾脏剂量学可能降低淋巴细胞减少风险并改善临床结局。

要点

  • 椎体V15、V2.5及脾脏V10与SBRT后≥2级淋巴细胞减少发生相关。
  • 椎体V15≥5.84%者≥2级淋巴细胞减少发生率为65.5% vs 34.0%(p=0.002)。
  • 椎体V2.5≥48.36%者为48.9% vs 23.8%(p=0.005),脾脏V10≥4.17%者为56.2% vs 26.9%(p<0.001)。

核心结论

  • 椎体与脾脏照射剂量增加与接受SBRT的BRPC/LAPC患者发生淋巴细胞减少相关。
  • 作者认为优化椎体与脾脏剂量学可能降低淋巴细胞减少风险并改善该人群临床结局。

研究设计与样本

  • 回顾性分析纳入132例接受SBRT且具备淋巴细胞计数与放疗计划可供回顾的BRPC/LAPC患者。
  • 对每例患者回顾性勾画T11-L3椎体与脾脏,行单变量与多变量分析,并生成受试者工作特征曲线确定预测≥2级淋巴细胞减少的剂量体积阈值。

主要发现

  • 多变量分析中,椎体V15(β=-0.026,95%CI -0.044至-0.009,p=0.003)、椎体V2.5(β=-0.011,95%CI -0.020至-0.002,p=0.015)及log10PTV(β=-0.15,95%CI -0.30至-0.005,p=0.042)与SBRT后绝对淋巴细胞计数相关。
  • 多变量分析中,椎体V15(OR 3.98,95%CI 1.09-14.51,p=0.027)、椎体V2.5(OR 1.04,95%CI 1.00-1.09,p=0.032)及脾脏V10(OR 1.05,95%CI 1.09-1.95,p=0.004)与≥2级淋巴细胞减少发生相关。
  • 椎体V15≥5.84%者≥2级淋巴细胞减少发生率为65.5% vs 34.0%(p=0.002)。
  • 椎体V2.5≥48.36%者发生率为48.9% vs 23.8%(p=0.005),脾脏V10≥4.17%者为56.2% vs 26.9%(p<0.001)。

关键数值与推荐

  • 椎体V15阈值5.84%用于区分≥2级淋巴细胞减少风险(65.5% vs 34.0%,p=0.002)。
  • 椎体V2.5阈值48.36%(48.9% vs 23.8%,p=0.005)与脾脏V10阈值4.17%(56.2% vs 26.9%,p<0.001)用于区分≥2级淋巴细胞减少风险。

临床怎么用

  • 作者认为优化椎体与脾脏剂量学可能降低淋巴细胞减少风险并改善该人群临床结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The purpose of this study was to determine if vertebral body and splenic dosimetry was associated with the development of lymphopenia in patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC) treated with stereotactic body radiation therapy (SBRT). METHODS: Patients with BRPC/LAPC who were treated with SBRT and who had lymphocyte counts and radiation treatment plans available for review were included in the study. Vertebral body levels T11-L3 and the spleen were retrospectively contoured for each patient. Univariate (UVA) and multivariable analyses (MVA) were performed to identify associations between vertebral body and splenic dosimetric parameters with absolute lymphocyte count (ALC) and grade ≥ 2 lymphopenia. Receiver operator characteristic curves were generated to identify dose-volume thresholds in predicting grade ≥ 2 lymphopenia. RESULTS: A total of 132 patients were included in the study. On UVA and MVA, vertebral V15 (regression coefficient [β]: - 0.026, 95% CI - 0.044 to - 0.009, p = 0.003), vertebral V2.5 (β: - 0.011, 95% CI - 0.020 to - 0.002, p = 0.015), and log10PTV (β: - 0.15, 95% CI - 0.30 to - 0.005, p = 0.042) were associated with post-SBRT ALC. On UVA and MVA, vertebral V15 (odds ratio [OR]: 3.98, 95% CI 1.09-14.51, p = 0.027), vertebral V2.5 (OR: 1.04, 95% CI 1.00-1.09, p = 0.032), and spleen V10 (OR: 1.05, 95% CI 1.09-1.95, p = 0.004) were associated with development of grade ≥ 2 lymphopenia. Development of grade ≥ 2 lymphopenia was more likely in patients with vertebral V15 ≥ 5.84% (65.5% vs 34.0%, p = 0.002), vertebral V2.5 ≥ 48.36% (48.9% vs 23.8%, p = 0.005), and spleen V10 ≥ 4.17% (56.2% vs 26.9%, p < 0.001). CONCLUSIONS: Increasing radiation dose to vertebral bodies and spleen were associated with the development of lymphopenia in BRPC/LAPC treated with SBRT. Optimization of vertebral body and splenic dosimetry may reduce the risk of developing lymphopenia and improve clinical outcomes in this population.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Reddy AV, Deek MP, Jackson JF, et al. Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. Radiat Oncol. 2021. PMID: 34952610. doi:10.1186/s13014-021-01969-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。